IBI-80090

In November, 2012 IBI received FDA approval of its Orphan Drug Designation for IBI-80090 (mephalan for intraocular injection) for the treatment of retinoblastoma.  IBI will be collaborating with Memorial Sloan Kettering Cancer Center on this project.

Share
Icon Bioscience, Inc. | 1253 Reamwood Ave. | Sunnyvale, CA | 94089 | 650-369-4049
Copyright © 2014 Icon Bioscience, Inc. · Optimization by MME ·